{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:22:31Z","timestamp":1789564951997,"version":"build-2803163510"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is a rare genetic disorder characterised by numerous renal cysts, the progressive expansion of which can impact kidney function and lead eventually to renal failure. Tolvaptan is the only disease-modifying drug approved for the treatment of ADPKD, however its poor side effect and safety profile necessitates the need for the development of new therapeutics in this area. Using a combination of transcriptomic and machine learning computational drug discovery tools, we predicted that a number of existing drugs could have utility in the treatment of ADPKD, and subsequently validated several of these drug predictions in established models of disease. We determined that the anthelmintic mebendazole was a potent anti-cystic agent in human cellular and <jats:italic>in vivo<\/jats:italic> models of ADPKD, and is likely acting through the inhibition of microtubule polymerisation and protein kinase activity. These findings demonstrate the utility of combining computational approaches to identify and understand potential new treatments for traditionally underserved rare diseases.<\/jats:p>","DOI":"10.3389\/fphar.2024.1397864","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T07:48:43Z","timestamp":1716450523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Philip W.","family":"Brownjohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azedine","family":"Zoufir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"O\u2019Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saatviga","family":"Sudhahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Syme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Huckvale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Bange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil T.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/genes14030678","article-title":"The role of PRMT5 in immuno-oncology","volume":"14","author":"Abe","year":"2023","journal-title":"Genes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/1878-0261.12810","article-title":"In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor","volume":"14","author":"Ariey-Bonnet","year":"2020","journal-title":"Mol. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1038\/s41598-020-61082-3","article-title":"A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells","volume":"10","author":"Asawa","year":"2020","journal-title":"Sci. Rep-uk"},{"key":"B4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"","journal-title":"Neuro-Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-14-2681","article-title":"Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model","volume":"21","author":"Bai","year":"","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1523-1755.2001.00768.x","article-title":"Angiogenesis in autosomal-dominant polycystic kidney disease","volume":"60","author":"Bello-Reuss","year":"2001","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22257","DOI":"10.1038\/s41598-023-48638-9","article-title":"Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort","volume":"13","author":"Calvaruso","year":"2023","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.3390\/molecules26175118","article-title":"Anticancer effect of benzimidazole derivatives, especially mebendazole, on triple-negative breast cancer (TNBC) and radiotherapy-resistant TNBC in vivo and in vitro","volume":"26","author":"Choi","year":"2021","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/febs.15473","article-title":"Microtubule-associated proteins and emerging links to primary cilium structure, assembly, maintenance, and disassembly","volume":"288","author":"Conkar","year":"2021","journal-title":"FEBS J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.kint.2023.01.026","article-title":"A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease","volume":"103","author":"Dagorn","year":"2023","journal-title":"Kidney Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.1021\/jm300576q","article-title":"Predicting new indications for approved drugs using a proteochemometric method","volume":"55","author":"Dakshanamurthy","year":"2012","journal-title":"J. Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B17","doi-asserted-by":"publisher","first-page":"109648","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell. Signal."},{"key":"B18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Gall","year":"2019","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1vdaa54","DOI":"10.1093\/noajnl\/vdaa154","article-title":"Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial","volume":"3","author":"Gallia","year":"2021","journal-title":"Neuro-oncology Adv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1073\/pnas.1204524109","article-title":"Identifying mechanism-of-action targets for drugs and probes","volume":"109","author":"Gregori-Puigjan\u00e9","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1074\/jbc.M507845200","article-title":"Polycystin-2 regulates proliferation and branching morphogenesis in kidney epithelial cells","volume":"281","author":"Grimm","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1042\/BJ20120768","article-title":"Protein arginine methyltransferase 5 is essential for growth of lung cancer cells","volume":"446","author":"Gu","year":"2012","journal-title":"Biochem. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1152\/physiolgenomics.00027.2016","article-title":"Heterotrimeric G protein signaling in polycystic kidney disease","volume":"48","author":"Hama","year":"2016","journal-title":"Physiol. Genom."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J. Clin. Investig."},{"key":"B26","doi-asserted-by":"publisher","first-page":"120536","DOI":"10.1016\/j.lfs.2022.120536","article-title":"Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer","volume":"299","author":"Hegazy","year":"2022","journal-title":"Life Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000448296","article-title":"Renin-angiotensin-aldosterone system antagonism and polycystic kidney disease progression","volume":"134","author":"Hian","year":"2016","journal-title":"Nephron"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e26726","DOI":"10.7554\/eLife.26726","article-title":"Systematic integration of biomedical knowledge prioritizes drugs for repurposing","volume":"6","author":"Himmelstein","year":"2017","journal-title":"eLife"},{"key":"B29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/s0140-6736(94)92344-2","article-title":"Mediation of renal cyst formation by hepatocyte growth factor","volume":"344","author":"Horie","year":"1994","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10884","DOI":"10.1074\/jbc.RA118.002377","article-title":"Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis","volume":"293","author":"Huang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2174\/1386207318666150803130138","article-title":"RepurposeVS: a drug repurposing-focused computational method for accurate drug-target signature predictions","volume":"18","author":"Issa","year":"2015","journal-title":"Comb. Chem. High. T Scr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.krcp.2012.07.002","article-title":"Mammalian target of rapamycin inhibition in polycystic kidney disease: from bench to bedside","volume":"31","author":"Kim","year":"2012","journal-title":"Kidney Res. Clin. Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"F1705","DOI":"10.1152\/ajprenal.00723.2012","article-title":"Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla","volume":"305","author":"Kortenoeven","year":"2013","journal-title":"Am. J. Physiol-renal"},{"key":"B35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0020-7519(88)90175-0","article-title":"The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles","volume":"18","author":"Lacey","year":"1988","journal-title":"Int. J. Parasitol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1093\/hmg\/ddm299","article-title":"Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice","volume":"16","author":"Leeuwen","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1681\/ASN.2016040425","article-title":"Variable cyst development in autosomal dominant polycystic kidney disease: the biologic context","volume":"27","author":"Leonhard","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1007\/s00018-015-2000-5","article-title":"Tubulin acetylation: responsible enzymes, biological functions and human diseases","volume":"72","author":"Li","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41401-022-00937-z","article-title":"1-Indanone retards cyst development in ADPKD mouse model by stabilizing tubulin and down-regulating anterograde transport of cilia","volume":"44","author":"Li","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e49418","DOI":"10.1371\/journal.pone.0049418","article-title":"HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE"},{"key":"B42","doi-asserted-by":"publisher","first-page":"102585","DOI":"10.1016\/j.ebiom.2019.11.046","article-title":"Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles","volume":"51","author":"Malas","year":"2020","journal-title":"EBioMedicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1038\/s41598-019-42806-6","article-title":"Drug prioritization using the semantic properties of a knowledge graph","volume":"9","author":"Malas","year":"2019","journal-title":"Sci. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.1038\/s41598-021-88433-y","article-title":"A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer","volume":"11","author":"Mansoori","year":"2021","journal-title":"Sci. Rep-uk"},{"key":"B45","doi-asserted-by":"publisher","first-page":"D613","DOI":"10.1093\/nar\/gkaa1024","article-title":"WikiPathways: connecting communities","volume":"49","author":"Martens","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"5","author":"Menezes","year":"2016","journal-title":"EBioMedicine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"F300","DOI":"10.1152\/ajprenal.1998.274.2.F300","article-title":"Microtubule disruption inhibits AVT-stimulated Cl\u2212 secretion but not Na+ reabsorption in A6 cells","volume":"274","author":"Morris","year":"1998","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the European rare kidney disease reference network and polycystic kidney disease international","volume":"37","author":"M\u00fcller","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"B49","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/bib\/bbw112","article-title":"A review of connectivity map and computational approaches in pharmacogenomics","volume":"19","author":"Musa","year":"2017","journal-title":"Brief. Bioinform."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s00432-013-1539-5","article-title":"Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer","volume":"139","author":"Nygren","year":"2013","journal-title":"J. Cancer Res. Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1752-0509-5-56","article-title":"Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease","volume":"5","author":"Pandey","year":"2011","journal-title":"BMC Syst. Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?","volume":"19","author":"Pisani","year":"2018","journal-title":"BMC Nephrol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.gendis.2022.04.001","article-title":"Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue","volume":"10","author":"Prabhu","year":"2023","journal-title":"Genes Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1172\/JCI41531","article-title":"Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease","volume":"120","author":"Qin","year":"2010","journal-title":"J. Clin. Invest."},{"key":"B56","doi-asserted-by":"publisher","first-page":"F773","DOI":"10.1152\/ajprenal.00058.2011","article-title":"Anti-VEGF antibody treatment accelerates polycystic kidney disease","volume":"301","author":"Raina","year":"2011","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am. J. Physiol-renal"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41467-021-21770-8","article-title":"Identification of disease treatment mechanisms through the multiscale interactome","volume":"12","author":"Ruiz","year":"2021","journal-title":"Nat. Commun."},{"key":"B60","first-page":"1201","article-title":"The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells","volume":"1","author":"Sasaki","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrneph.2015.46","article-title":"The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease","volume":"11","author":"Seeger-Nukpezah","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0190430","DOI":"10.1371\/journal.pone.0190430","article-title":"The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition","volume":"13","author":"Solazzo","year":"2018","journal-title":"Plos One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-3-319-51436-9_12","article-title":"Inflammation and fibrosis in polycystic kidney disease","volume":"60","author":"Song","year":"2017","journal-title":"Cell Differ."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","article-title":"Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks","volume":"18","author":"Song","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1058825","DOI":"10.3389\/fmolb.2023.1058825","article-title":"Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model","volume":"10","author":"Song","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"Spithoven","year":"","journal-title":"Kidney Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"109649","DOI":"10.1016\/j.cellsig.2020.109649","article-title":"Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling","volume":"72","author":"Sussman","year":"2020","journal-title":"Cell. Signal."},{"key":"B69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1254\/jphs.12117fp","article-title":"Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized Guinea pigs","volume":"120","author":"Takahara","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"32714","DOI":"10.1074\/jbc.M603126200","article-title":"Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor","volume":"281","author":"Tanos","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5002550","article-title":"VEGF receptor inhibition slows the progression of polycystic kidney disease","volume":"72","author":"Tao","year":"2007","journal-title":"Kidney Int."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"New Engl. J. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"","journal-title":"New Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Hastel","year":"2017","journal-title":"Ann. Nutr. Metab."},{"key":"B77","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Wang","year":"2013","journal-title":"BMC Bioinforma."},{"key":"B79","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1073\/pnas.1311784110","article-title":"PRMT5 dimethylates R30 of the p65 subunit to activate NF-\u03baB","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10020-023-00664-z","article-title":"Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion","volume":"29","author":"Wilk","year":"2023","journal-title":"Mol. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013\u20132015","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.18632\/oncotarget.28014","article-title":"Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer","volume":"12","author":"Williamson","year":"2021","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","first-page":"a028159","DOI":"10.1101\/cshperspect.a028159","article-title":"Posttranslational modifications of tubulin and cilia","volume":"9","author":"Wloga","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/368750a0","article-title":"Taxol inhibits progression of congenital polycystic kidney disease","volume":"368","author":"Woo","year":"1994","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.M117.803775","article-title":"Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease","volume":"292","author":"Yanda","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1681\/ASN.2020040511","article-title":"Cyclin-dependent kinase 1 activity is a driver of cyst growth in polycystic kidney disease","volume":"32","author":"Zhang","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1128\/MCB.01154-06","article-title":"Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally","volume":"28","author":"Zhang","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"109646","DOI":"10.1016\/j.cellsig.2020.109646","article-title":"Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease","volume":"72","author":"Zhang","year":"2020","journal-title":"Cell. Signal."},{"key":"B91","doi-asserted-by":"publisher","first-page":"8407","DOI":"10.1021\/acs.jmedchem.3c00250","article-title":"Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies","volume":"66","author":"Zheng","year":"2023","journal-title":"J. Med. Chem."},{"key":"B92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.15586\/codon.pkd.2015.ch9","volume-title":"Apoptosis in polycystic kidney disease: from pathogenesis to treatment","author":"Zhou","year":"2015"},{"key":"B93","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1053\/j.akdh.2023.01.003","article-title":"Autosomal dominant polycystic kidney disease therapies on the horizon","volume":"30","author":"Zhou","year":"2023","journal-title":"Adv. Kidney Dis. Heal."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/hmg\/ddt556","article-title":"SIRT2 regulates ciliogenesis and contributes to abnormal centrosome amplification caused by loss of polycystin-1","volume":"23","author":"Zhou","year":"2014","journal-title":"Hum. Mol. Genet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1397864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T07:48:49Z","timestamp":1716450529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1397864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":94,"alternative-id":["10.3389\/fphar.2024.1397864"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1397864","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"article-number":"1397864"}}